Inflammasome-related markers at the ICU admission are not associated with outcome in the critically ill COVID-19 patients.

Barbara Adamik[1] barbara.adamik@umed.wroc.pl

Magdalena Ambrożek-Latecka[2] magdalena.ambrozek-latecka@cmkp.edu.pl

Barbara Dragan[1] barbara.dragan@umed.wroc.pl

Aldona Jeznach[3] aldona.jeznach@cmkp.edu.pl

Jakub Śmiechowicz[1] jakub.smiechowicz@umed.wroc.pl

Waldemar Goździk[1] waldemar.gozdzik@umed.wroc.pl

Tomasz Skirecki[2,3*] tskirecki@cmkp.edu.pl

[1] Department of the Anaesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland;

[2]Department of Clinical Cytology, Centre of Postgraduate Medical Education, Warsaw, Poland

[3]Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland

Correspondence: Tomasz Skirecki

Laboratory of Flow Cytometry

Centre of Postgraduate Medical Education

Marymoncka 99/103

01-813 Warsaw

Poland

Tel +48 22 5693830

Fax +48 22 5693700

Email tskirecki@cmkp.edu.pl

Abstract:

Purpose: Development of targeted biological therapies for COVID-19 requires reliable

biomarkers that could help indicate the responding patients. Hyperactivation of the inflammasome

by SARS-CoV2 virus is hypothesized to contribute to severe course of the COVID-19 disease.

Therefore, we aimed to evaluate the prognostic value of several inflammasome-related cytokines

and proteins at the admission to the intensive care unit (ICU).

Patients and methods: Plasma samples were obtained from 45 critically ill COVID-19 patients

and from 10 patients any without any signs of infection (TBI, traumatic brain injury) on admission

to the ICU. The concentration of IL-1α, IL-1β, IL-18, IL-1RA, galectin-1, ASC, LDH, ferritin, and

gasdermin D were analyzed. A novel cell-free caspase-1 plasma assay was developed by

inhibitor-based immunoprecipitation followed by Western Blot. Demographic and clinical

characteristics were recorded.

Results: In-hospital mortality in COVID-19 patients reached 62%. Galectin-1 was 1.8-fold lower

in COVID-19 than in TBI patients (17101.84 vs. 30764.20 pg/ml, p=0.007), but other

inflammasome-related biomarkers were at similar concentrations. Patients with SOFA score of >9

on admission who were at high risk of death had significantly higher galectin-1 but lower IL-1RA

in comparison to low-risk patients (25551.3 pg/ml vs 16302.7 pg/ml, p=0.014; 14.5 pg/ml vs 39.4

pg/ml, p=0.04, respectively). Statistically significant correlations were observed between: IL-1α

and platelets (r=-0.37), IL-1β and platelets (r=-0.36), ferritin and INR (r=0.39). Activated caspase-

1 p35 was detectable in 12/22 COVID-19 patients but in none of the TBI patients. Its presence

was related with higher fibrinogen and lower D-dimers. Moreover, the densitometric analysis

showed a significantly higher amount of p35 in patients with SOFA> 9.

Conclusion: Our results indicate that the systemic markers of activation of the inflammasome in

critically ill COVID-19 patients is not directly related with outcome. Therefore, potential

interventions aimed at the inflammasome pathway in this group of patients may be of limited

effectiveness and should be biomarker-guided.

Keywords: SARS-CoV2, biomarker, inflammation, caspase-1, critical care, interleukin-1

Introduction

Infection with the respiratory SARS-CoV2 virus causes the coronavirus disease 2019 (COVID-19) which ranges from asymptomatic infection through mild and severe disease (pneumonia) to critical disease which has a form of the acute respiratory distress syndrome (ARDS) or sepsis and septic shock[1]. This range of severity is reflected by the mortality ranges which reaches approx. 40% in critically ill patients[2]. Although other coronavirues can infect humans, the COVID-19 is characterized by unique pathogenesis making it a distinct disease[3]. Aside from respiratory support, the only widely accepted treatment for COVID-19 is dexamethasone and recently tocilizumab[1].

There is an urgent need to develop efficient therapies for COVID-19 and it becomes apparent that as in the case of bacterial sepsis, a biomarker-guided personalized approach is a prerequisite for successful biological therapies[4]. Since early pandemics we among others have proposed that the unbalanced inflammasome signaling may be a key process in the pathogenesis of COVID-19[5,6]. Briefly, inflammasomes are multiprotein complexes activated by various stimuli such as dsDNA (Absent in Melanoma, AIM2), potassium efflux and reactive oxygen species (NLR Family Pyrin Domain Containing 3, NLRP3)[7]. Upon activation, the receptor proteins oligomerize and recruit adaptor proteins (apoptosis-associated speck-like protein, ASC) and pro-caspase-1. Then pro-caspase-1 undergoes autoproteolysis to its active form which then can cleave pro-interleukin-1α, β, -18 and gasdermin D (GSDMD). N-terminal GSDMD can form pores in the cell membrane which leads to the release of the cleaved cytokines as well as other molecules (such as lactate dehydrogenase; alarmins) and lytic cell death called pyroptosis[7]. Indeed, it has been demonstrated that the inflammasome is activated in the lungs of COVID-19 patients[8,9] and can be activated in the circulating monocytes[10]. However, the status of inflammasome reactivity in the blood myeloid cells appears complexed[11]. Although some studies showed an increase in concentrations of pro-inflammatory cytokines with increasing severity of COVID-19[12], there is a limited number of studies focused on critically ill COVID-19 patients who are at the highest risk of death. Nevertheless, there are ongoing clinical trials with direct (Dapansutrile, Colchicine)

inflammasome inhibitors and indirect (Disulfiram, a GSDMD inhibitor). Also, recently two studies

on the IL-1R antagonist in COVID-19 were published with opposite results[13,14].

In this study, we aimed to evaluate the prognostic utility of selected plasma proteins

related to inflammasome activation in critically ill COVID-19 patients. Considering the high

mortality and lack of effective therapies we focused on the critically ill COVID-19 patients at the

admission to intensive care unit (ICU). We hypothesized that biomarkers of good accuracy could

serve to guide immunomodulatory therapies targeting the inflammasomes.

91 Material and methods

92 *Patients*

We have prospectively collected samples from 45 patients with critical COVID-19 at the

admission to ICU of the Wroclaw Medical University. Critical COVID-19 was defined according to

COVID-19 treatment guidelines[1]. Briefly, the patients filled criteria for acute respiratory distress

syndrome (ARDS), sepsis, septic shock, and required introduction of life-sustaining therapies[1].

SARS-CoV2 infection was confirmed by real-time reverse-transcriptase polymerase chain

reaction (RT-PCR) assay of nasal or pharyngeal swab probes. All patients were treated according

to the WHO guidelines[1]. All patients were administered intravenous dexamethasone at a dose of

6 mg per day. The study protocol complies with the 1975 Declaration of Helsinki as revised in

1983. The Wroclaw Medical University Bioethics Committee approved this study (consent No.

394/2021). The Committee also approved the collection of plasma from the traumatic brain injury

(TBI) (consent No.KB-391/2015). Written informed consent was obtained from the patient or a

legally authorized representative. Blood samples collected from patients with TBI were used to

compare markers of inflammasome activation between cases with SARS-CoV2 infection (COVID-

19 group) and cases without any signs of infection (TBI group). The clinical status of the patients

was determined with the Acute Physiology and Chronic Health Evaluation (APACHE) II score and

Sequential Organ Failure Assessment (SOFA) score on admission to the ICU. The APACHE II

score it is routinely used as a prediction tool for ICU patients and includes 12 physiological variables (the fraction of inspired oxygen, partial pressure of oxygen, body temperature, mean arterial pressure, blood pH, heart rate, respiratory rate, serum sodium, serum potassium, serum creatinine, hematocrit, white blood cell count, and the Glasgow Coma Scale) and 2 disease-related variables (the history of severe organ failure or immunocompromised and the type of ICU admission). The SOFA score is routinely used in the ICU for monitoring the severity of patient's clinical condition based on the status of the following systems: respiratory (PaO_2/FiO_2 index), cardiovascular (mean arterial pressure and the dose of vasopressors), hepatic (bilirubin level), coagulation (platelets level), renal (creatinine level/urine output), and neurological (Glasgow coma scale).

Cytokine analysis

The blood samples were collected via routinely inserted arterial cannula. 2.7 ml of peripheral blood was collected into 0,109 M sodium citrate containing tubes (BD Vacutainer, BD, NJ, USA). Plasma was collected after centrifugation at 2000 x g for 10 minutes and stored at -70°C. IL-1α, IL-1β, IL-18, IL-1RA and galectin-1 concentrations were analyzed by Milliplex Human Multiplex Assay (Merck, Germany) using the Magpix System. ACS protein was analyzed using the commercially available ELISA kit (Cusabio Technology, TX, USA). Human GSDMD was analyzed using commercial ELISA kit (Abclonal, MA, USA). Other analytes were measured at the certified hospital clinical laboratory.

Caspase-1 immunoprecipitation

Equal volumes of plasma (200 µl) from Controls (TBI) and COVID-19 patients were treated with 50 µM Biotin-FAD-FMK (SantaCruz Biotechnology, CA, USA) with gentle rotation at 4°C overnight. Then, 10 µl of Streptavidin Sepharose Bead Conjugate (Cell Signalling Technology, MA, USA) was added to plasma samples and incubated for 5h with gentle rotation at 4°C. The biotin-streptavidin bead complexes were centrifuged for 5 min at 2300 x g and washed 5 times

using 1 x Ripa Lysis buffer (Millipore) supplemented with Protease Inhibitor Cocktail (Millipore)

and 1 mM PMSF. Pellet samples were suspended in 4 x Laemmli buffer and boiled for 3 min in

94°C. For detection of the active forms' caspase-1 the pulled down immunocomplexes were

separated in 15 % SDS - PAGE gels following by wet electrotransfer onto PVDF membranes.

Non-specific bindings were blocked in TBS-T with 5 % non – fat milk for 1 h in room temperature.

Membranes were incubated with anti – Caspase-1 (cleaved 297; 1:1000 dilution; GenTex)

overnight at 4°C. Rabbit polyclonal antibody (1: 10000 dilution; Vector Laboratories, Inc.) was

used to detect primary antibody. Signals were visualized by WesternBright® ECL HRP substrate

(Advansta) using UVITEC gel documentation system. Densitometric analysis was done by

GelAnalyzer 19.1.

Statistical analysis

Normality of data was tested using the Shapiro-Wilk test. Continuous variables are expressed as

median values and interquartile ranges whereas categorical variables are presented as

frequencies with percentages. Categorical variables were compared using the Fisher's exact test.

Continuous variables were compared using the Mann-Whitney test. Receiver operating

characteristic (ROC) curves were constructed to calculate area under the curve (AUC) of the

investigated parameters. The cut-off values were indicated using the Youden's index method.

Correlations between variables were tested using the Spearman's test. Logistic regression

analysis was performed to test the relationship between biomarkers and the risk of death or

development of secondary infections. Statistica 13.1 software was used for calculations and

GraphpadPrism 9.0 was used to create graphs. Statistical significance was determined as $p <$

0.05.

Results

Clinical characteristics of the patient's population

We have enrolled forty-five critically ill COVID-19 patients with RT-PCR confirmed SARS-CoV2

infection. The clinical and demographic characteristic of the group is presented in **Tab. 1**. This

group included 24 males (53%) and 21 females and the median age was 58 years (IQ: 43-68). At

admission, the patients' median APACHE II score was 14 (IQ: 11-22) and SOFA score was 9

(IQ:7-10). The hospital mortality reached 62% and was higher than 28-day mortality which was

53%. The patients who did not survive were significantly older (median 64 (IQ:52-70) vs. 50 (IQ:

33-60) yrs.) and had higher APACHE II score in comparison to the survivors (20 (IQ:14-25) vs. 12

(IQ:8-13)). Most common comorbidities were hypertension and cancer; however, their occurrence

was not related with survival. The extra corporeal membrane oxygenation (ECMO) therapy was

used in 29% of non-survivors and 18% of survivors. Twelve patients were admitted with co-

infections with *Acinetobacter baumannii* and *Candida albicans* being the most common

pathogens (3/12 each) followed by the methicillin-resistant *Staphylococcus aureus* (MRSA, 2/12).

Twenty-one patients (47%) developed secondary infections with *A. baumannii* and *C. albicans* as

the most frequent pathogens (6/21 each) followed by MRSA and *Stenotrophomonas maltophilia*

(4/21 each).

Markers of inflammasome activation are not outcome-related in critically ill COVID-19 patients

Markers of inflammasome activation are not outcome-related in

critically ill COVID-19 patients

Firstly, we have compared the levels of IL-1α, IL-1β, IL-18, IL-1RA, galectin-1, ASC and

gasdermin D in the study group with the age and sex matched group of traumatic brain injury

(TBI) patients. Interestingly, only galectin-1 was significantly different in the critically ill COVID-19

patients in comparison to TBI patients (17101.84 (IQ: 10836.62 - 25551.30) pg/ml vs. 30764.20

(IQ: 23150.67 - 35759.48) pg/ml; p=0.007; **Fig. 1**). Then, we compared the concentration of the

inflammasome related markers between COVID-19 survivors and non-survivors. Neither of the

proteins could differentiate between these groups (**Fig. 2).** Moreover, LDH and ferritin which can

serve as surrogate markers of cell death and IL-1 signaling, respectively, were not increased in

patients with unfavorable outcome (**Tab. 2**). Other routinely monitored markers of inflammation as

white blood count, IL-6 or CRP were also similar in these two groups. Of the analyzed

parameters, only the international normalized ratio (INR) was significantly higher in the non-

surviving COVID-19 patients. However, logistic regression analysis did not reveal the relationship

between INR either other analyzed parameters and mortality (p>0.05). Also, there were no

difference in the concentrations of the analyzed biomarkers of the inflammasome response

between patients who were admitted with co-infections and those who were not. These results

indicate that inflammasome-related proteins are less elevated in critically ill COVID-19 patients at

ICU admission than in TBI patients and are not different between survivors and non-survivors.

Galectin-1 and IL-1RA can stratify the severity of critically ill

COVID-19 at the admission

As the SOFA score is one of the most widely used tools to stratify the critically ill patients

including COVID-19, we analyzed its predictive capacity in our group of patients. Indeed, the

ROC analysis for in-hospital mortality was characterized by the area under the curve (AUC) of

0.824 (95%CI: 0.703 - 0.944) which is of moderate accuracy [15]. As a predictor of death, the SOFA

score of 9 points was characterized by the sensitivity of 75.0% and specificity of 64.7%. Then, we

applied this cut-off point to divide the patients into two groups of high- and low-risk of death. The

high-risk patients had significantly higher level of galectin-1 in comparison to individuals at low-

risk (25551.30 (IQ: 15628.85 - 41048.02) pg/ml vs. 16302.72 (IQ: 8785.86 - 22040.25) pg/ml;

p=0.014, respectively). Interestingly, the high-risk group had significantly lower level of IL-1RA in

comparison to the low-risk patients (14.50 (IQ: 9.28 - 47.01) vs. 39.35 (IQ: 17.87 - 88.01) pg/ml;

p=0.047). The high-risk group patients were also characterized by higher white blood count

(17.00 (IQ: 13.40 - 20.30) x10^6/ml vs. 12.75 (IQ: 10.20 - 16.80) x10^6/ml; p=0.034), procalcitonin

(2.10 (IQ: 0.40 - 4.00) ng/mL vs 0.25 (IQ: 0.11 - 0.60) ng/L; p=0.001 and IL-6 (700.00 (IQ: 680.70

- 1890.00) pg/ml vs. 66.60 (IQ: 16.00 - 107.00) pg/ml; p=0.001). The frequency of co-infections

was not significantly different between these groups, however chronic comorbidities such as

coronary artery disease, heart failure and renal disease were significantly more common in the

high-risk patients. Of interest, patients who developed secondary infections had lower level of

galectin-1 than those who did not (14908.51 (IQ: 8394.48 - 21,911.48) pg/ml vs. 23,839.62 (IQ:

15,628.85 - 29,846.66) pg/ml; p=0.039, however logistic regression analysis did not confirm this

relationship (OR=1.00, p=0.042). There were no differences among analyzed inflammasome-

related biomarkers either standard inflammatory parameters (IL-6, PCT, WBC) between patients

who developed secondary infections during ICU stay and those who did not. Altogether, these

results suggest that the threshold of 9 SOFA score points indicated low- and high-risk critically ill

COVID-19 patients who differed in the inflammasome and inflammatory profile.

Correlations of the inflammasome-related markers with other

inflammatory markers in the critically ill COVID-19

Additionally, we tested whether the concentrations of the inflammasome-related proteins are

related with other measures. The Spearman's correlation test revealed a weak but significant

correlation between IL-1α and IL-1β (r=0.40) and between IL-18 and IL-1RA (r=0.60) and

galectin-1 (r=0.27). Gasdermin D correlated with the ASC protein (r=0.44) and ferritin correlated

with INR (r=0.39) and LDH (r=0.45). There was also inverse correlation between IL-1α and

platelets and IL-1β and platelets count (r=-0.37 and r=-0.36, respectively). No significant

correlations were found between the inflammasome-related markers and CRP, PCT, nor IL-6.

These observations support the hypothesis that the plasma concentration of analyzed

inflammasome-related proteins are concomitantly regulated and reflect the same cellular

processes.

Cell free caspase-1 is not ubiquitously present in the

circulation of critical COVID-19 patients

As secretion of IL-1 and pyroptosis can result from the activation of other than inflammasome

cellular pathways[16] we decided to confirm the activation of inflammasome in the COVID-19

patients by development of inhibitor-based immunoprecipitation of active caspase-1 followed by

Western Blot detection of the specific fragments. Interestingly, the dominant form of caspase-1

present in the plasma was the intermediate form p35 found in 12 of 22 COVID -19 patients (**Fig.**

3A) while it was undetectable in TBI patients. In six of 22 COVID-19 patients also mature p20

form could be detected (**Fig. 3A**). Presence of active caspase-1 was not related with outcome

neither severity of the disease. There was also no difference in caspase-1 between patients with

coinfections. However, patients at high-risk of death defined by SOFA score >9 had significantly

higher amount of p35 in densitometric analysis (**Fig. 3B**) Of interest, patients with detectable p35

had higher fibrinogen level (7.30 g/L (IQ: 5.50 - 8.70) vs. 5.45 g/L (IQ: 4.10 - 6.30); p=0.020) and

lower d-dimers (1.35 μg/mL (IQ: 1.20 - 4.35) vs. 10.25 μg/mL (IQ: 6.30 - 20.90); p=0.019).

Discussion

Our study is the first to our best knowledge that have investigated comprehensively the

plasma biomarkers related with inflammasome regulation in a well-defined group of critically ill

COVID-19 patients at the ICU admission. We found that the marked activation of inflammasome

defined as presence of active capsase-1 in the patient's plasma is not ubiquitous and not related

with outcome. Also, other quantitative inflammasome-related proteins and cytokines are not

related with outcome and only galectin-1 and IL-1RA differed in patients with low- and high-risk of

death.

In this study we have focused on the critically ill COVID-19 patients at admission to ICU

as this group is at high risk of death (reflected by 28-day mortality of 53% outreached by in-

hospital mortality of 62% in our group). Although many groups have tried to identify new potential

biomarkers, we have selected a panel of proteins related with different stages of the

inflammasome activity. It included the structural component of inflammasome, the ASC protein;

effector proteins cleaved by caspase-1 (IL-1α, IL-1β, IL-18), their antagonist IL-1RA and

gasdermin D which forms pyroptotic pores in cell membrane. Also, we measured galectin-1 and

LDH which are markers of inflammatory cell death[17] and ferritin which is induced by the

inflammasome activity[18]. Moreover, we have established a new method to analyze active

caspase-1 from human plasma which is based on the immunoprecipitation with biotinylated FAD-

FMK, a pan-caspase inhibitor followed by Western Blot to specifically detected caspase-1 forms.

The concentration of the measures cytokines was not different between critical COVID-19

and TBI patients. We choose the TBI patients for comparison as it relatively homogenous group

with sterile injury, age- and sex-matched. ASC, IL-1 and capase-1 were already shown to be

upregulated in plasma of TBI patients [19]. Although increased galectin-1 was already described in

COVID-19 patients [20] it was compared to healthy controls only. Here, we found higher galectin-1

in TBI patients than COVID-19 which suggests that the latter is not characterized by extreme

over-inflammatory response as suggested by some authors[3,21]. Our results expand the findings of

others showing similar levels of inflammatory cytokines in COVID-19 and sepsis or other critical

conditions [22-24].

Neither of the analyzed protein was related with mortality in critically ill COVID-19

patients. Although some of these cytokines like IL-18 or IL-1RA were already linked with the

severity of COVID-19[9,25,26] it should be highlighted that our study is focused on a defined

population of critical COVID-19 in contrast to most studies which compare cytokine levels in early

COVID-19 of various severity. As the analyzed cytokines can be produced in inflammasome-

independent manner, we assessed the presence of active caspase-1. We have detected the

intermediate p35 form of caspase-1 in 54% cases and mature p20 in 27% patients. These finding

clearly indicate that level of inflammasome activation is heterogenous in critical COVID-19 and

complete maturation of caspase-1 is not common in these patients. The status of circulating

caspase-1 was not related with outcome similarly to the findings by the group of D. Zamboni who

utilized capsase-1 ELISA[9]. Even less frequently we were able to detect the ASC and GSDMD

proteins which also indicates infrequent activation of inflammasome in critical COVID-19. Our

results stay in accordance with recent findings that showed only small percentage of NLRP3 and

AIM2 inflammasome activation in the circulating monocytes from COVID-19 patients[10,27].

Moreover, current data point at monocytes and macrophages as the major lung cell types

showing activation of the inflammasome in COVID-19[9,10]. Additionally, we compared

inflammasome-related proteins in the patients divided by their SOFA score at admission with the

most accurate threshold to predict mortality (low- and high-risk groups). Notably, galectin-1 and

caspae-1 p35 was increased in the high-risk group, while IL-1RA was decreased. Such pattern

may suggest indeed loss of control of this inflammatory pathway in the high-risk group of patients.

The high-risk patients had also higher leukocyte count, IL-6, procalcitonin and INR however,

neither of these parameters was significantly related with outcome in logistic regression model.

As inflammasomes are reported to play role in the susceptibility to secondary

infections[28,29] we tested for the relation between inflammasome activation markers and co-

infections or development of secondary infections however, there were no significant correlations

between these variables. We observed some weak but significant correlations between IL-1α and

IL-1β, ASC and GSDMD, ferritin and LDH which suggests coordinated regulation of these

mediators. Interestingly, we observed links between the inflammasome activity and dysregulated

coagulation system. Patients with unfavorable prognosis had marks of coagulopathy indicated by

higher INR values. In addition, there was a correlation between ferritin and INR and inversed

correlation between IL-1α and IL-1β and platelets. Altogether, these observations suggest

mechanistic link between inflammasome activation and coagulopathy and possibly features of

secondary hemophagocytic lymphohistiocytosis[3].

This study has several limitations related with small patients' group and lack of

mechanistic investigations. Noteworthy, our study group is well-defined and limited to the ARDS

and sepsis forms of COVID-19. Although we analyzed several proteins related with activation of

the inflammasome we did not measure other relevant mediators that can interact with this

pathway (e.g. interferons). The present study would also benefit from the flow cytometry data of

the inflammasome activation in circulating blood cells. Moreover, we analyzed only plasma

proteins and it should be noted that they may not fully reflect the tissue response. Finally, we

were not able to explain the heterogenic pattern of the inflammasome activity in these patients.

319   Conclusion

Our findings are of important clinical relevance as inflammasome-targeted therapies are

widely testes in COVID-19, mostly without the use of biomarker guidance. Recently, the negative

results of the collaborative trial on the colchicine (which inhibits inflammasome formation[30]) were

published[31]. Also, trials targeting IL-1 in severe COVID-19 with anakinra was reported to be

negative[14]. At the same time, another study that used su-PAR levels to guide the anakinra

treatment in early COVID-19 showed significant benefit[13]. The results of these studies are not

surprising in the light of our findings showing heterogeneity in inflammasome activation in

critically ill COVID-19 patients and lack of its direct relation with mortality. Yet, it could be

speculated that in a selected subpopulation of patients with activated caspase-1 or high galectin-

1 level these therapies could turn beneficial. Nevertheless, further mechanistic studies on the role

of inflammasome in the pathogenesis of COVID-19 are needed.

Funding

333   Study funded by the Polish National Science Centre grant no: UMO-2020/01/0/NZ6/00218

334   (COVID-19) and by Wroclaw Medical University (Poland), grant number STM.A170.01.037.

Authors contribution

337   All authors made substantial contributions to conception and design, acquisition of data, or

338   analysis and interpretation of data; took part in drafting the article or revising it critically for

339   important intellectual content; agreed to submit to the current journal; gave final approval of the

340   version to be published; and agree to be accountable for all aspects of the work.

Disclosure

342   The author reports no conflicts of interest in this work.

References

1.   https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed
19/10/2021
, 2021.
2.   Armstrong RA, Kane AD, Kursumovic E, Oglesby FC, Cook TM. Mortality in patients
admitted to intensive care with COVID-19: an updated systematic review and meta-
analysis of observational studies. *Anaesthesia.* 2021;76(4):537-548.
3.   Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering
pathophysiology and phenotypes of a new disease entity. *Lancet Respir Med.*
2021;9(6):622-642.
4.   Cavaillon JM, Singer M, Skirecki T. Sepsis therapies: learning from 30 years of failure of
translational research to propose new leads. *EMBO Mol Med.* 2020;12(4):e10128.
5.   Osuchowski MF, Aletti F, Cavaillon JM, et al. SARS-CoV-2/COVID-19: Evolving Reality,
Global Response, Knowledge Gaps, and Opportunities. *Shock.* 2020;54(4):416-437.
6.   Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic
Targets for COVID-19. *J Immunol.* 2020;205(2):307-312.
7.   Xue Y, Enosi Tuipulotu D, Tan WH, Kay C, Man SM. Emerging Activators and Regulators
of Inflammasomes and Pyroptosis. *Trends Immunol.* 2019;40(11):1035-1052.
8.   Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the lungs of patients with
fatal COVID-19. *Inflamm Res.* 2021;70(1):7-10.
9.   Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response
to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp*
Med. 2021;218(3).
10.   Junqueira C, Crespo A, Ranjbar S, et al. SARS-CoV-2 infects blood monocytes to
activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. *medRxiv.*
2021.
11.   Ferreira AC, Soares VC, de Azevedo-Quintanilha IG, et al. SARS-CoV-2 engages
inflammasome and pyroptosis in human primary monocytes. *Cell Death Discov.*
2021;7(1):43.
12.   Herr C, Mang S, Mozafari B, et al. Distinct Patterns of Blood Cytokines Beyond a
Cytokine Storm Predict Mortality in COVID-19. *J Inflamm Res.* 2021;14:4651-4667.
13.   Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with
anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-
blind, randomized controlled phase 3 trial. *Nat Med.* 2021.
14.   Investigators TR-C, Derde LPG. Effectiveness of Tocilizumab, Sarilumab, and Anakinra
for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation
Therapy Domain Randomized Clinical Trial. *medRxiv.* 2021:2021.2006.2018.21259133.
15.   Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of
diagnostic test properties: clinical example of sepsis. *Intensive Care Med.*
2003;29(7):1043-1051.
16.   Pyrillou K, Burzynski LC, Clarke MCH. Alternative Pathways of IL-1 Activation, and Its
Role in Health and Disease. *Front Immunol.* 2020;11:613170.
17.   Russo AJ, Vasudevan SO, Mendez-Huergo SP, et al. Intracellular immune sensing
promotes inflammation via gasdermin D-driven release of a lectin alarmin. *Nat Immunol.*
2021;22(2):154-165.
18.   Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol.*
2017;29(9):401-409.
19.   Kerr N, Lee SW, Perez-Barcena J, et al. Inflammasome proteins as biomarkers of
traumatic brain injury. *PLoS One.* 2018;13(12):e0210128.
20.   Kazancioglu S, Yilmaz FM, Bastug A, et al. Assessment of Galectin-1, Galectin-3, and
PGE2 Levels in Patients with COVID-19. *Jpn J Infect Dis.* 2021.
21.   Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current
Evidence and Treatment Strategies. *Front Immunol.* 2020;11:1708.

22. Wilson JG, Simpson LJ, Ferreira AM, et al. Cytokine profile in plasma of severe COVID-
19 does not differ from ARDS and sepsis. *JCI Insight.* 2020;5(17).
23. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically
Ill Patients With COVID-19 and Other Conditions. *JAMA.* 2020.
24. Stolarski AE, Kim J, Zhang Q, Remick DG. Reply Letter to The Editor Regarding:
Cytokine Drizzle-The Rationale for Abandoning The Term Cytokine Storm. *Shock.*
2021;56(5):873-874.
25. Satis H, Ozger HS, Aysert Yildiz P, et al. Prognostic value of interleukin-18 and its
association with other inflammatory markers and disease severity in COVID-19. *Cytokine.*
2021;137:155302.
26. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-
10 with disease severity and RANTES with mild disease. *JCI Insight.* 2020;5(13).
27. Courjon J, Dufies O, Robert A, et al. Heterogeneous NLRP3 inflammasome signature in
circulating myeloid cells as a biomarker of COVID-19 severity. *Blood Adv.*
2021;5(5):1523-1534.
28. Roth S, Cao J, Singh V, et al. Post-injury immunosuppression and secondary infections
are caused by an AIM2 inflammasome-driven signaling cascade. *Immunity.*
2021;54(4):648-659 e648.
29. Martinez-Garcia JJ, Martinez-Banaclocha H, Angosto-Bazarra D, et al. P2X7 receptor
induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome
activation during sepsis. *Nat Commun.* 2019;10(1):2711.
30. Magupalli VG, Negro R, Tian Y, et al. HDAC6 mediates an aggresome-like mechanism
for NLRP3 and pyrin inflammasome activation. *Science.* 2020;369(6510).
31. Group RC. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a
randomised, controlled, open-label, platform trial. *The Lancet Respiratory Medicine.*
2021.
424
425
426

427 **Table 1** Clinical and demographical characteristics of the critically ill COVID-19 patients

Characteristic	survivors (n=17)	non-survivors (n=28)	p
Age	50 (33-60)	64 (52-70)	**0.0030**
Sex (male), n (%)	8 (47)	16 (57)	0.1248
Hospitalization days	28 (13-45)	17 (7-28)	**0.0349**
ICU days	21 (6-35)	12 (4-18)	0.2508
28-day mortality	0	24	0.1336
SOFA score	7 (6-9)	9 (8-12)	0.0024
APACHE II score	12 (8-13)	20 (14-25)	**0.0001**
Comorbidities:			
Co-infections n (%)	3 (18)	9 (33)	0.4295
Cancer, n (%)	0 (0)	5 (18)	0.0773
Hypertension, n (%)	8 (47)	14 (50)	0.8482
Diabetes, n (%)	2 (12)	5 (18)	0.6931
Asthma, n (%)	1 (6)	3 (10)	1.0000
COPD, n (%)	0 (0)	1 (4)	1.0000
Obesity, n (%)	3 (18)	3 (10)	0.6581
Coronary artery disease, n (%)	0 (0)	4 (15)	0.2812
Chronic renal disease, n (%)	0 (0)	2 (7)	0.7029
Pregnancy, n (%)	3 (18)	0 (0)	**0.0160**
Secondary infections	9 (53)	12 (42)	0.7522

Treatment:			
CRRT, n (%)	0 (0)	6 (21)	0.1100
ECMO, n (%)	3 (18)	8 (29)	0.6390

430   **Abbreviations:** CCRT, continuous renal-replacement therapy; COPD, chronic obstructive

431   pulmonary disease; ECMO, extra corporeal membrane oxigenation; ICU, intensive care unit;.

453 **Table 2** Laboratory findings in the critically ill COVID-19 patients at the ICU admission

Characteristic	survivors (n=17)	non-survivors (n=28)	p
White blood count [x10^6/L]	12.9 (10.8-15.5)	15.7 (11.6-18.9)	0.3736
Platelets [x10^9/L]	287 (216-311)	241 (178-332)	0.2323
APTT [seconds]	33.1 (30.6-38.8)	36.0 (30.6-42.9)	0.3800
INR	1.10 (1.05-1.17)	1.24 (1.15-1.37)	**0.0095**
D-dimers [ug/ml]	1.80 (1.20-7.00)	6.45 (1.90-23.70)	0.0918
C-reactive protein [mg/L]	109.0 (67.0-149.0)	110.0 (67.5-195.0)	0.8149
Procalcitonin [ng/mL]	0.30 (0.11-0.43)	0.51 (0.14-1.95)	0.1528
Interleukin-6 [pg/ml]	75.85 (10.40-217.00)	88.80 (40.05-1001.50)	0.1939
Glucose [mg/dL]	136.0 (107.0-159.0)	172.5 (127.0-214.0)	0.1340
Ferritin [ng/ml]	698.5 (292.5-1563.5)	1156.0 (568.0-2002.0)	0.2089
Lactate dehydrogenase [U/L]	618.0 (480.0-709.0)	583.0 (427.0-930.0)	0.9906
Galectin-1 [pg/ml]	16424 (12957-22040)	21760 (10759-29643)	0.4329
IL-1α [pg/ml]	4.80 (4.80-11.97)	5.46 (4.80-8.68)	0.9905
IL-1β [pg/ml]	7.39 (2.69-11.46)	8.08 (2.69-13.23)	0.9252
IL-1RA [pg/ml]	43.11 (17.87-68.17)	23.26 (10.71-87.75)	0.7519
IL-18 [pg/ml]	57.78 (41.11-94.15)	66.58 (24.14-96.61)	0.9160
ASC [pg/ml]	0.00 (0.00-0.00)	76.70 (18.70-134.700)	1.0000
GSDMD [pg/ml]	0.02 (0.02-0.27)	0.010 (0.06-0.12)	0.5509

Abbreviations: APTT, activated partial thromboplastin time; ASC, apoptosis-associated speck-

like containing a CARD; GSDMD, gasdermin D.

Figure 1. Comparison of the inflammasome-related markers in the traumatic brain injury

(TBI) and critical COVID-19 patients. A. Interleukin-1α. B. Interleukin-1β. C. Interleukin-18. D.

Interleukin-1 Receptor Antagonist. E. Apoptosis-associated speck-like protein containing a

CARD. F. Gasdermin D. G. Galectin-1. Concentrations of plasma proteins were compared

between TBI patients (n=10) with critically ill COVID-19 (n=45) with the Mann-Whitney test.

**p<0.05.

Figure 2. Inflammasome-related markers in the plasma of critically ill COVID-19 patients at

low- and high risk of death. The high risk of death was stratified by the threshold of more than 9

points in SOFA score. A. Interleukin-1α. B. Interleukin-1β. C. Interleukin-18. D. Interleukin-1

Receptor Antagonist. E. Apoptosis-associated speck-like protein containing a CARD. F.

Gasdermin D. G. Galectin-1. H. Lactate Dehydrogenase. I. Ferritin. Concentrations of plasma

proteins were compared between patients at high risk (n=15) with patients at low risk of death

(n=30) with the Mann-Whitney test. *p<0.05.

Figure 3. **Active caspase-1 is unambiguously present in critical COVID-19 patient's plasma.**

A. Representative immunoblots with labeled with anti-caspase-1 of the pull-downed FAD-FMK

bonded caspases from the plasma of TBI patients (3TBI, 5 TBI) and COVID-19 patients (numbers

8-22). The mature p20 band is present in approx. half of the patients with intermediate p35 form.

B. Patients at high risk of death (SOFA>9) had more circulating p35 as revealed by densitometric

analysis. Data were compared with the Mann-Whitney test. *p<0.05.

A

B